Trials / Recruiting
RecruitingNCT07293260
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 406 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 35 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olpasiran | Olpasiran will be administered SC. |
| DRUG | Placebo | Placebo will be administered SC. |
Timeline
- Start date
- 2026-03-23
- Primary completion
- 2028-06-15
- Completion
- 2028-06-15
- First posted
- 2025-12-19
- Last updated
- 2026-04-16
Locations
40 sites across 11 countries: United States, Australia, Canada, China, Denmark, France, Germany, Italy, Japan, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07293260. Inclusion in this directory is not an endorsement.